Eugene Chang
Retina Specialist · Pasadena, CANPI 1265432991
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,383 of the $10,167 with a category attached, or 62.8%. 29 manufacturers reported payments, led by Alcon at 32.2% of the total.
Across 115 payments — averaging $88.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Intuitive Surgical$896
- Bausch & Lomb Americas Inc.$756
- AbbVie$544
- Regeneron Healthcare Solutions, Inc.$543
- Aerie Pharmaceuticals, Inc.$511
- plus $4K from 23 others
Across 29 payments — averaging $15,244 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$425K
- Eyepoint US, Inc.$17K
What the payments were for
- Speaking & faculty fees$2,85028%
- Travel & lodging$8969%
- Food & beverage$6,38363%
- Education$380%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 8 | $3,270 |
| Intuitive Surgical | 3 | $896 |
| Bausch & Lomb Americas Inc. | 8 | $756 |
| AbbVie(2 entities) | 7 | $544 |
| Regeneron Healthcare Solutions, Inc. | 6 | $543 |
| Aerie Pharmaceuticals, Inc. | 10 | $511 |
| Astellas Pharma US Inc | 15 | $436 |
| Sun Pharmaceutical Industries Inc. | 6 | $433 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $411 |
| Eyepoint US, Inc. | 3 | $335 |
| Sight Sciences, Inc. | 2 | $273 |
| Alimera Sciences, Inc. | 6 | $262 |
| Genentech USA, Inc. | 5 | $231 |
| ANI Pharmaceuticals, Inc. | 5 | $212 |
| Apellis Pharmaceuticals, Inc. | 3 | $165 |
| Tarsus Pharmaceuticals, Inc. | 3 | $153 |
| Amgen | 1 | $146 |
| Ocular Therapeutix, Inc. | 2 | $125 |
| Oyster Point Pharma, Inc. | 4 | $115 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $113 |
| Glaukos Corporation | 1 | $45 |
| Genentech, Inc. | 1 | $38 |
| Exactech, Inc. | 1 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Thea Pharma Inc. | 1 | $25 |
| Boston Scientific | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Optos, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$877
- Rhopressa$599
- Rocklatan$599
- CEQUA$375
- YUTIQ$271
- MIEBO$250
- XIIDRA$250
- VYZULTA$250
- EYLEA HD$247
- STELLARIS$236
- EYLEA$228
- DEXYCU$166
- TearCare SmartLid$148
- TEARCARE(TM) (2.2) SYSTEM KIT$148
- TEPEZZA$146
- VABYSMO$134
- LOTEMAX SM$125
- OMNI(R) SURGICAL SYSTEM (US)$125
- RESTASIS MULTIDOSE$125
- VUITY$125
How this compares
$10,167 in reported general payments places this provider in the 70th percentile of 187 retina specialist providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 38 | $31,817 |
| RhopressaNetarsudil Mesylate | 60 | $23,499 |
| Alphagan PBrimonidine Tartrate | 57 | $23,493 |
| LumiganBimatoprost | 40 | $23,051 |
| Cyclosporine | 39 | $20,772 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 958 | $19,987 |
| ProlensaBromfenac Sodium | 53 | $18,352 |
| Prednisolone Acetate | 325 | $14,365 |
| BromsiteBromfenac Sodium | 52 | $13,890 |
| RocklatanNetarsudil Mesylat/Latanoprost | 32 | $13,262 |
| Brimonidine Tartrate | 463 | $13,142 |
| Latanoprost | 1,054 | $12,108 |
| VyzultaLatanoprostene Bunod | 17 | $11,169 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $6,547 |
| Bromfenac Sodium | 25 | $5,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P, Lumigan, Combigan | $544 | $84,908149 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $511 | $36,76192 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $411 | $18,35253 claims |
| Sun Pharmaceutical Industries Inc.Bromsite | $433 | $13,89052 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $756 | $11,16917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 187 retina specialist providers in California.
Other retina specialist in Pasadena
- Sahar BedroodPasadena$297K
- Payam AminiPasadena$11K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Baruch KuppermannIrvine$1M
- Carlos Medina MendezSacramento$548K
- Michael JavaheriBeverly Hills$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.